menu
    • menu
    [{"orgOrder":0,"company":"Monopar Therapeutics","sponsor":"RA Capital Management","pharmaFlowCategory":"D","therapeuticArea":"Genetic Disease","country":"U.S.A","productType":"Other Small Molecule","year":"2024","type":"Public Offering","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase III","graph3":"Monopar Therapeutics","amount2":0.040000000000000001,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0.040000000000000001,"dosageForm":"Oral Tablet","sponsorNew":"Monopar Therapeutics \/ RA Capital Management","highestDevelopmentStatusID":"10","companyTruncated":"Monopar Therapeutics \/ RA Capital Management"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Alexion Pharmaceuticals","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tiomolibdate Choline","moa":"Copper chelating agent","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Alexion Pharmaceuticals","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Alexion Pharmaceuticals"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2021","type":"Inapplicable","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"},{"orgOrder":0,"company":"AstraZeneca","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Genetic Disease","country":"UNITED KINGDOM","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Tiomolibdate Choline","moa":"Copper","graph1":"Genetic Disease","graph2":"Phase III","graph3":"AstraZeneca","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Genetic Disease","amount2New":0,"dosageForm":"Oral Tablet","sponsorNew":"AstraZeneca \/ Inapplicable","highestDevelopmentStatusID":"10","companyTruncated":"AstraZeneca \/ Inapplicable"}]

    Find Clinical Drug Pipeline Developments & Deals for Tiomolibdate Choline

    Menu

    Tiomolibdate Choline

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Monopar Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            Monopar Therapeutics

                            U.S.A arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tiomolibdate Choline

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : RA Capital Management

                            Deal Size : $40.0 million

                            Deal Type : Public Offering

                            DEALS_DEV arrow-down

                            Monopar Completes $40M Public Offering and Private Pre-Funded Warrant Placement

                            Details : Monopar intends to use the net proceeds from the offering for clinical development of late-stage ALXN-1840 (tiomolibdate choline), which is being evaluated for the treatment of Wilson disease.

                            Product Name : ALXN-1840

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            December 20, 2024

                            Lead Product(s) : Tiomolibdate Choline

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : RA Capital Management

                            Deal Size : $40.0 million

                            Deal Type : Public Offering

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            AstraZeneca

                            United Kingdom arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tiomolibdate Choline

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Alexion Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilization From Tissues, Potentially Closing Treatm...

                            Details : ALXN1840 (WTX101) is a potential new once-daily, oral medicine in development for the treatment of Wilson disease. This investigational, novel molecule is designed to selectively and tightly bind to and remove copper from the body’s tissues and blood.

                            Product Name : ALXN1840

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 27, 2022

                            Lead Product(s) : Tiomolibdate Choline

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Alexion Pharmaceuticals

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            AstraZeneca

                            United Kingdom arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tiomolibdate Choline

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            ALXN1840 Shows Rapid and Sustained Improvement in Copper Mobilisation From Tissues, Potentially Closing Treatm...

                            Details : Results from positive FoCus trial in Wilson disease showed that WTX101 (ALXN1840), met its primary endpoint demonstrating three-times greater copper mobilisation from tissues compared to SoC including in patients who had been treated previously for an av...

                            Product Name : WTX-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            June 23, 2022

                            Lead Product(s) : Tiomolibdate Choline

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            AstraZeneca

                            United Kingdom arrow
                            Peptide Therapy Summit
                            Not Confirmed

                            AstraZeneca

                            United Kingdom arrow
                            Peptide Therapy Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Tiomolibdate Choline

                            Therapeutic Area : Genetic Disease

                            Study Phase : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            AstraZeneca’s Phase III FoCus Trial of ALXN1840 to Treat Wilson Disease Meets Primary Endpoints Showing Impr...

                            Details : ALXN1840, a potential new once-daily, oral medicine, demonstrated approximately three times greater copper mobilisation than SoC. ALXN1840 demonstrated approximately three times greater copper mobilisation from tissues than standard-of-care treatments.

                            Product Name : WTX-101

                            Product Type : Other Small Molecule

                            Upfront Cash : Inapplicable

                            August 26, 2021

                            Lead Product(s) : Tiomolibdate Choline

                            Therapeutic Area : Genetic Disease

                            Highest Development Status : Phase III

                            Sponsor : Inapplicable

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth